Cisplatin in renal transplant recipients : not an absolute contraindication
Abstract
The chemotherapeutic agent cisplatin is usually contraindicated in renal transplant recipients due to its well-known side effect of nephrotoxicity, but is an important (and sometimes irreplaceable) drug in the management of cancer. We report a case of cisplatin usage concurrently with radiation (CRT) in unresectable head and neck cancer, along with a review of the literature.
Rights
OpenAccess.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.